Using a special virus to improve treatment for advanced pancreatic cancer
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC
This study is exploring a new way to treat pancreatic cancer using specially designed viruses that can target and destroy cancer cells, aiming to offer better options for patients with advanced disease who have few treatments available.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10987059 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer with a low survival rate. The study aims to utilize oncolytic adenoviruses, which are viruses engineered to selectively target and kill cancer cells, while overcoming challenges associated with delivering these viruses systemically. By modifying the adenovirus to enhance its ability to reach and affect tumor cells, the research seeks to provide a more effective treatment option for patients with advanced PDAC who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced pancreatic ductal adenocarcinoma who are not eligible for surgical intervention.
Not a fit: Patients with early-stage pancreatic cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective systemic therapies for patients with advanced pancreatic cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using oncolytic viruses for cancer treatment, indicating that this approach could be a viable option for PDAC.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Yamamoto, Masato — University of Minnesota
- Study coordinator: Yamamoto, Masato
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.